RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

RAD001

"Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD."

DRUG

Imatinib

Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.

Trial Locations (1)

48109

University of Michigan Health System, Ann Arbor

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER